-
-
-
-
-
-
-
Plus Therapeutics subsidiary gets Medicare enrollment for diagnostic test
-
-
-
-
-
-
-
Plus Therapeutics outlines 2026 goals for REYOBIQ trials and CNSide rollout
-
-
-
-
-
-
-
Plus Therapeutics gets 180-day extension for NASDAQ compliance
-
-
-
-
-
-
-
D. Boral Capital Upgrades Plus Therapeutics Inc. (PSTV) to Buy
-
-
-
-
-
-
-
Plus Therapeutics launches CNSide diagnostic in Texas
-
-
-
-
-
-
-
Plus Therapeutics (PSTV) Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM
-
-
-
-
-
-
-
Plus Therapeutics (PSTV) Appoints Kyle Guse to its Board
-
416,816 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

